07 August 2025 : Database Analysis
Trends and Efficacy in Clostridioides difficile Infection Management at a Polish Clinical Hospital
Jarosław Drobnik
ABDEG 1, Piotr Pobrotyn ADEFG 2*, Urszula Grata-Borkowska DF 1, Katarzyna Madziarska DE 3, Mateusz Baran ABCDEF 4
DOI: 10.12659/MSM.948254
Med Sci Monit 2025; 31:e948254
Table 1 Analysis of antimicrobial therapy used for CDI at the UCHW in 2016–2018.
| Method of treatment | Number of patients | Percentage of patients |
|---|---|---|
| They did not receive medication against CDI | 10 | 3.16 |
| Metronidazole only | 85 | 26.90 |
| Vancomycin only | 65 | 20.57 |
| Metronidazole and vancomycin | 128 | 40.51 |
| Rifaximin and metronidazole | 2 | 0.63 |
| Rifaximin and vancomycin | 5 | 1.58 |
| Rifaximin and metronidazole and vancomycin | 16 | 5.06 |
| Fidaxomicin and metronidazole | 0 | 0.00 |
| Fidaxomicin and vancomycin | 2 | 0.63 |
| Fidaxomicin and metronidazole and vancomycin | 3 | 0.95 |